CA2327526A1 - Agents thrombolytiques derives de streptokinase - Google Patents

Agents thrombolytiques derives de streptokinase Download PDF

Info

Publication number
CA2327526A1
CA2327526A1 CA002327526A CA2327526A CA2327526A1 CA 2327526 A1 CA2327526 A1 CA 2327526A1 CA 002327526 A CA002327526 A CA 002327526A CA 2327526 A CA2327526 A CA 2327526A CA 2327526 A1 CA2327526 A1 CA 2327526A1
Authority
CA
Canada
Prior art keywords
ser
gly
pro
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002327526A
Other languages
English (en)
Inventor
Xuejun C. Zhang
Xinli Lin
Jordan J. N. Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2327526A1 publication Critical patent/CA2327526A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des données de structure relatives au complexe streptokinase/micro-plasminogène ont permis d'identifier la partie de la structure de la streptokinase qui n'intervient pas dans la complexation ou l'activation du plasminogène. Il est possible de modifier ces parties non essentielles de façon à réduire l'antigénicité, en transformant par exemple les parties non essentielles de la streptokinase en parties polypeptidiques d'origine apparemment humaine (? humanisation de la streptokinase ?). Pour ce faire, on peut comparer la partie non essentielle à une base de données structurelles de protéines humaines afin d'identifier des structures similaires. On remplace ensuite la partie structurelle non essentielle de la streptokinase par la partie structurelle humaine, par exemple en manipulant génétiquement un mutant codant pour les streptokinases individuelles, qui est ensuite exprimé dans un hôte bactérien tel que E. coli. Il est également possible de retirer ou de supprimer les parties non essentielles pour simplifier la streptokinase en la transformant en une molécule plus petite qui conserve l'activité d'activation du plasminogène. Ces petites molécules possèdent une antigénicité réduite et peuvent être produites plus facilement et de manière peu onéreuse. Les streptokinases modifiées s'avèrent utiles au traitement des troubles de la coagulation.
CA002327526A 1998-05-06 1999-05-06 Agents thrombolytiques derives de streptokinase Abandoned CA2327526A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8439298P 1998-05-06 1998-05-06
US60/084,392 1998-05-06
PCT/US1999/010086 WO1999057251A2 (fr) 1998-05-06 1999-05-06 Agents thrombolytiques derives de streptokinase

Publications (1)

Publication Number Publication Date
CA2327526A1 true CA2327526A1 (fr) 1999-11-11

Family

ID=22184683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002327526A Abandoned CA2327526A1 (fr) 1998-05-06 1999-05-06 Agents thrombolytiques derives de streptokinase

Country Status (5)

Country Link
EP (1) EP1078044A2 (fr)
JP (1) JP2002513810A (fr)
AU (1) AU4072399A (fr)
CA (1) CA2327526A1 (fr)
WO (1) WO1999057251A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397366A1 (fr) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Streptokinases hybrides avec des domaines de liaison pour la fibrine et méthodes pour leur synthèse
US5240845A (en) * 1989-07-11 1993-08-31 Otsuka Pharmaceutical Factory, Ltd. Mutated streptokinase proteins
WO1994007992A1 (fr) * 1992-10-05 1994-04-14 The General Hospital Corporation Peptides se liant specifiquement a des plasminogenes et adn codant de tels peptides
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase
AU1829599A (en) * 1997-12-15 1999-07-05 Presidents and Fellows of Harvard College, The Bacterial fibrin-dependent plasminogen activator

Also Published As

Publication number Publication date
JP2002513810A (ja) 2002-05-14
AU4072399A (en) 1999-11-23
EP1078044A2 (fr) 2001-02-28
WO1999057251A3 (fr) 1999-12-16
WO1999057251A2 (fr) 1999-11-11

Similar Documents

Publication Publication Date Title
US20020055459A1 (en) Crystal structure of bace and uses thereof
EP2314308A1 (fr) Utilisation de microprotéines comme inhibiteurs de tryptase
EP3124496B1 (fr) Mutants de streptokinase et leurs formes modifiées de manière covalente
WO2002038162A1 (fr) FACTEUR VIIa MODIFIÉ
US7666627B2 (en) Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
Tang et al. Crystal structure of earthworm fibrinolytic enzyme component a: revealing the structural determinants of its dual fibrinolytic activity
EP4165181A2 (fr) Compositions et procédés associés au facteur i du complément
AU766970B2 (en) Tissue factor protein variants with increased affinity for coagulation factor FVII/FVIIa
JP2005508295A (ja) Ｉｇｆ結合タンパク質の変異体、およびそれらのアゴニストの作製法
Groves et al. A 2.3 A resolution structure of chymosin complexed with a reduced bond inhibitor shows that the active site beta-hairpin flap is rearranged when compared with the native crystal structure.
US20100267638A1 (en) Exosite-directed thrombin inhibitors
CA2327526A1 (fr) Agents thrombolytiques derives de streptokinase
EP1203014A2 (fr) ANTAGONISTE PEPTIDE DU FACTEUR FVIIa
Dewilde et al. High quality structure of cleaved PAI-1-stab
JP2003508049A (ja) Ｃｄｃ２５の阻害物質を同定する方法
CA2162986A1 (fr) Proteines possedant des proprietes fibrinolytiques et anticoagulantes
JP4149208B2 (ja) 血栓の溶解を制御するペプチドおよびその利用
Ward et al. Complex interactions between bovine plasminogen and streptococcal plasminogen activator PauA
Acquasaliente et al. From haemadin to haemanorm: Synthesis and characterization of full‐length haemadin from the leech Haemadipsa sylvestris and of a novel bivalent, highly potent thrombin inhibitor (haemanorm)
Beck Plasminogen Activation, Conformation, and Binding in the Context of Group A Streptococcus Virulence Factors, Streptokinase and PAM
CA2353699A1 (fr) Activateur de plasminogene humain
US7164002B2 (en) FVIIa antagonists
US20070299013A1 (en) Exosite-Directed Thrombin Inhibitors
WO2004064709A2 (fr) Agent thrombolytique
Mouat Biochemical and structural characterization of Streptococcus pyogenes C5a peptidase: a thesis presented in partial fulfillment of the requirements for the degree of Master of Science in Biochemistry at Massey University

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead